European Institute for Molecular Imaging (EIMI), Westfälische Wilhelms-University Münster, Münster, Germany.
Imagerie Moléculaire In Vivo, Inserm, CEA, Univ. Paris Sud, CNRS, Université Paris Saclay, CEA - Service Hospitalier Frédéric Joliot, Orsay, France.
Cancer Res. 2017 Apr 15;77(8):1831-1841. doi: 10.1158/0008-5472.CAN-16-2628. Epub 2017 Jan 30.
The tumor microenvironment is highly heterogeneous. For gliomas, the tumor-associated inflammatory response is pivotal to support growth and invasion. Factors of glioma growth, inflammation, and invasion, such as the translocator protein (TSPO) and matrix metalloproteinases (MMP), may serve as specific imaging biomarkers of the glioma microenvironment. In this study, noninvasive imaging by PET with [F]DPA-714 (TSPO) and [F]BR-351 (MMP) was used for the assessment of localization and quantification of the expression of TSPO and MMP. Imaging was performed in addition to established clinical imaging biomarker of active tumor volume ([F]FET) in conjunction with MRI. We hypothesized that each imaging biomarker revealed distinct areas of the heterogeneous glioma tissue in a mouse model of human glioma. Tracers were found to be increased 1.4- to 1.7-fold, with [F]FET showing the biggest volume as depicted by a thresholding-based, volumes of interest analysis. Tumor areas, which could not be detected by a single tracer and/or MRI parameter alone, were measured. Specific compartments of [F]DPA-714 (14%) and [F]BR-351 (11%) volumes along the tumor rim could be identified. [F]DPA-714 (TSPO) and [F]BR-351 (MMP) matched with histology. Glioma-associated microglia/macrophages (GAM) were identified as TSPO and MMP sources. Multitracer and multimodal molecular imaging approaches may allow us to gain important insights into glioma-associated inflammation (GAM, MMP). Moreover, this noninvasive technique enables characterization of the glioma microenvironment with respect to the disease-driving cellular compartments at the various disease stages. .
肿瘤微环境高度异质。对于神经胶质瘤,肿瘤相关炎症反应对支持生长和侵袭至关重要。神经胶质瘤生长、炎症和侵袭的因素,如转位蛋白(TSPO)和基质金属蛋白酶(MMP),可作为神经胶质瘤微环境的特异性成像生物标志物。在这项研究中,使用[F]DPA-714(TSPO)和[F]BR-351(MMP)的 PET 进行非侵入性成像,以评估 TSPO 和 MMP 的表达定位和定量。成像与 MRI 相结合,与现有的活跃肿瘤体积的临床成像生物标志物[F]FET 一起进行。我们假设,每个成像生物标志物都揭示了人类神经胶质瘤小鼠模型中异质神经胶质瘤组织的不同区域。示踪剂的增加幅度在 1.4 到 1.7 倍之间,[F]FET 显示出最大的体积,这是基于阈值的、基于感兴趣区的体积分析。测量了无法单独通过单个示踪剂和/或 MRI 参数检测到的肿瘤区域。可以识别[F]DPA-714(TSPO)(14%)和[F]BR-351(MMP)(11%)肿瘤边缘体积的特定隔室。[F]DPA-714(TSPO)和[F]BR-351(MMP)与组织学相匹配。神经胶质瘤相关的小胶质细胞/巨噬细胞(GAM)被鉴定为 TSPO 和 MMP 的来源。多示踪剂和多模态分子成像方法可以帮助我们深入了解神经胶质瘤相关炎症(GAM、MMP)。此外,这种非侵入性技术能够根据各种疾病阶段的疾病驱动细胞隔室来描述神经胶质瘤微环境。